The rise of GLP-1 receptor agonist medications—including Wegovy (semaglutide), Ozempic, Mounjaro (tirzepatide), and Zepbound—has revolutionized weight management. However, for pilots, these medications come with important FAA considerations that must be understood before starting treatment.
FAA Policy Snapshot
The FAA has established specific guidelines for pilots using GLP-1 medications. As of 2025, these medications are not automatically disqualifying, but pilots must meet certain requirements:
- Minimum 48-hour grounding period after each dose adjustment
- Stable dosing for at least 30 days before flying
- No significant side effects (nausea, hypoglycemia, cognitive changes)
- Documentation from prescribing physician
Grounding and Waiting Periods
When starting or adjusting GLP-1 medications, pilots should observe these waiting periods:
| Medication | Initial Grounding | Dose Adjustment |
|---|---|---|
| Wegovy/Ozempic | 7 days | 48 hours |
| Mounjaro/Zepbound | 7 days | 48 hours |
Documentation Requirements
Pilots using GLP-1 medications should maintain:
- Letter from prescribing physician confirming stable dosing
- Documentation of any side effects experienced
- Weight and metabolic monitoring records
- AME consultation notes
AME Counseling Checklist
During your FAA medical exam, be prepared to discuss:
- Reason for starting the medication
- Current dose and stability
- Any hypoglycemic episodes
- Gastrointestinal side effects
- Impact on cognitive function
Bottom Line
GLP-1 medications can be compatible with flying, but pilots must approach them responsibly. Work closely with your AME and prescribing physician to ensure you meet all FAA requirements. When in doubt, ground yourself until you are confident in your medication tolerance.
Questions about GLP-1 medications and your medical certificate?
References
- FAA Guide for Aviation Medical Examiners
- FAA Medical Certification Information
- Aerospace Medical Association Position Statement on Obesity Management